Tapinarof cream 1% once daily, a topical aryl hydrocarbon receptor (AhR)-modulating agent was recently approved by the FDA for the treatment of plaque psoriasis. touchIMMUNOLOGY were delighted to speak with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, USA) to learn more about the unmet needs in the treatment of plaque psoriasis, the rationale for the use of tapinarof cream 1% in this indication and how the recent FDA approval will impact the treatment paradigm.
This information is provided solely by Touch Medical Media and is independent of any sponsorship or affiliation with the European Academy of Dermatology & Venereology (EADV).
The abstract ‘Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Improvements in Quality of Life and Clinical Efficacy in Two Pivotal Phase 3 Trials.’ (Abstract number: 1175) was presented at EADV 2022, 7-10 September, 2022.
Questions
- What are the unmet needs in the treatment of plaque psoriasis? (0:17)
- What is the mechanism of action of Tapinarof cream 1% and the rationale for its use in plaque psoriasis? (0:51)
- Following FDA approval, where does Tapinarof cream 1% fit in the treatment paradigm for plaque psoriasis? (1:28)
Disclosures: Linda Stein Gold discloses consulting for Dermavant, Arcutis, Leo and Ortho Derm; receiving grant/ research support from Dermavant, Arcutis, Leo and Ortho Derm; serving on advisory boards for Dermavant, Arcutis, Leo and Ortho Derm; receiving honoraria from Dermavant, Arcutis, Leo and Ortho Derm and participating in speaker’s bureaus for Dermavant, Arcutis, Leo and Ortho Derm.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EADV meeting 2022.
